We are live on ! Find out more
SOCM

SR One Capital Management Portfolio holdings

AUM $1.04B
1-Year Est. Return 262.99%
This Fund
S&P 500
This Quarter Est. Return
+37.77%
1 Year Est. Return
+262.99%
3 Year Est. Return
+655.88%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$915M
AUM Growth
+$209M
Cap. Flow
+$121M
Cap. Flow %
13.23%
Top 10 Hldgs %
96.5%
Holding
14
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MANE
Veradermics Inc
MANE
+$121M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$269M 29.43%
2,346,630
– –
MANE
2
Veradermics Inc
MANE
$4.64B
$152M 16.57%
+2,401,868
New +$121M
ZBIO
3
Zenas BioPharma
ZBIO
$1.84B
$98.5M 10.76%
5,037,854
– –
CRSP icon
4
CRISPR Therapeutics
CRSP
$5.22B
$97M 10.59%
2,038,763
– –
DSGN icon
5
Design Therapeutics
DSGN
$901M
$69.4M 7.59%
6,526,476
– –
ORIC icon
6
Oric Pharmaceuticals
ORIC
$1.42B
$58.5M 6.39%
4,514,929
– –
ALMS
7
Alumis Inc
ALMS
$3.11B
$43.2M 4.72%
1,959,896
– –
MLYS icon
8
Mineralys Therapeutics
MLYS
$2.31B
$42.4M 4.63%
1,563,966
– –
SPRY icon
9
ARS Pharmaceuticals
SPRY
$606M
$32.2M 3.52%
4,012,903
– –
ORKA
10
Oruka Therapeutics
ORKA
$7.16B
$21.1M 2.31%
430,330
– –
OCS icon
11
Oculis Holding
OCS
$712M
$17M 1.86%
641,022
– –
NKTX icon
12
Nkarta
NKTX
$165M
$7.03M 0.77%
3,333,333
– –
ENGN icon
13
enGene Therapeutics
ENGN
$113M
$5.09M 0.56%
747,750
– –
RARE icon
14
Ultragenyx Pharmaceutical
RARE
$2.6B
$2.89M 0.32%
137,753
– –

Similar funds

CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
SM
Scoggin Management New York $1.04B AUM 232.32% 1-Year Est. Return
RC
RDST Capital Seattle, Washington $1.04B AUM 0.4% 1-Year Est. Return
OPFM
Optimus Prime Fund Management Grand Cayman, Cayman Islands $1.04B AUM 9.64% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
HWCM
Hudson Way Capital Management Dallas, Texas $1.05B AUM 6.84% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return

SR One Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, SR One Capital Management held 14 positions worth $915M, up 30% from $706M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

SR One Capital Management deployed $121M of net new capital in Q1 2026, opening 1 new position. Its largest new stake was Veradermics Inc: 2,401,868 shares worth $152M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • SR One Capital Management's largest Q1 2026 buy was Veradermics Inc: 2,401,868 shares worth $152M.
  • SR One Capital Management's ten largest holdings make up 96% of its $915M portfolio in Q1 2026.
  • SR One Capital Management opened 1 new position and closed 0 in Q1 2026.
  • SR One Capital Management's portfolio value rose 30% quarter-over-quarter to $915M.

Based on SR One Capital Management's 13F filing for Q1 2026, filed 14 May 2026.